06/05/23 8:00 AMOTC : ADXS clinical triallow floatUpdated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingData show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Company to host conference call and webcast to discuss updated Phase 2 results on Wednesday, June 7 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., June 05, 2023RHEA-AIneutral
05/25/23 5:05 PMOTC : ADXS clinical triallow floatAyala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingASCO abstract highlights 50% partial response and 100% disease control rates in evaluable desmoid tumor patients treated with AL102 1.2 mg once daily (the selected Phase 3 dose) Tumor response, volume and T2 signal reduction were observed earlier in the 1.2 mg once daily group, with deeper andRHEA-AIneutral
05/23/23 1:20 PMOTC : ADXS earningslow floatAyala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate UpdateAyala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced first-quarter 2023 financial results and provided a corporate update. “Our immediate priority is to complete enrollment inRHEA-AIneutral
04/27/23 8:00 AMOTC : ADXS low floatAyala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingAyala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it willRHEA-AIneutral
03/03/23 8:00 AMOTC : ADXS clinical triallow floatAyala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring CommitteeAyala Pharmaceuticals, Inc.RHEA-AIneutral
02/10/23 7:00 AMOTC : ADXS earningslow floatAyala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New Ayala,” “we,” “us” or “our”) (OTCQX: ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended OctoberRHEA-AIpositive
01/19/23 9:37 AMOTC : ADXS, ADXSD acquisitionlow floatAdvaxis and Ayala Pharmaceuticals Complete MergerAdvaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered ListeriaRHEA-AIneutral
01/12/23 8:04 AMOTC : ADXS, ADXSD clinical triallow floatAdvaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate CancerDose escalation has been completed and enrollment at second dose level will be expanded at Columbia University ADXS-504 has been well tolerated with no serious adverse events reported Four out of six patients treated are still on study and PSA values are being followed up MONMOUTH JUNCTION, N.J.,RHEA-AIneutral
10/19/22 6:30 AMOTC : ADXS, ADXSD acquisitionlow floatAdvaxis and Ayala Pharmaceuticals Enter into Merger AgreementMerger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62 .5% and 37 .5 %RHEA-AIpositive
09/12/22 6:40 PMOTC : ADXS, ADXSD earningslow floatAdvaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business UpdateRHEA-AIneutral